Literature DB >> 29802366

(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.

Jun-Ichi Yamaguchi1, Hidetoh Toki1, Youge Qu2, Chun Yang2, Hiroyuki Koike1, Kenji Hashimoto2, Akiko Mizuno-Yasuhira1, Shigeyuki Chaki3.   

Abstract

(R,S)-Ketamine has rapid and sustained antidepressant effects in depressed patients. Although the metabolism of (R,S)-ketamine to (2 R,6 R)-hydroxynorketamine (HNK), a metabolite of (R)-ketamine, has been reported to be essential for its antidepressant effects, recent evidence suggests otherwise. The present study investigated the role of the metabolism of (R)-ketamine to (2 R,6 R)-HNK in the antidepressant actions of (R)-ketamine. Antidepressant effects were evaluated using the forced swimming test in the lipopolysaccharide (LPS)-induced inflammation model of mice and the tail suspension test in naive mice. To prevent the metabolism of (R)-ketamine to (2 R,6 R)-HNK, mice were pretreated with cytochrome P450 (CYP) inhibitors. The concentrations of (R)-ketamine, (R)-norketamine, and (2 R,6 R)-HNK in plasma, brain, and cerebrospinal fluid (CSF) samples were determined using enantioselective liquid chromatography-tandem mass spectrometry. The concentrations of (R)-norketamine and (2 R,6 R)-HNK in plasma, brain, and CSF samples after administration of (R)-norketamine (10 mg/kg) and (2 R,6 R)-HNK (10 mg/kg), respectively, were higher than those generated after administration of (R)-ketamine (10 mg/kg). Nonetheless, while (R)-ketamine attenuated, neither (R)-norketamine nor (2 R,6 R)-HNK significantly altered immobility times of LPS-treated mice. Treatment with CYP inhibitors prior to administration of (R)-ketamine increased the plasma levels of (R)-ketamine, while generation of (2 R,6 R)-HNK was almost completely blocked. (R)-Ketamine exerted the antidepressant effects at a lower dose in the presence of CYP inhibitors than in their absence, which is consistent with exposure levels of (R)-ketamine but not (2 R,6 R)-HNK. These results indicate that metabolism to (2 R,6 R)-HNK is not necessary for the antidepressant effects of (R)-ketamine and that unmetabolized (R)-ketamine itself may be responsible for its antidepressant actions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29802366      PMCID: PMC6046044          DOI: 10.1038/s41386-018-0084-y

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  27 in total

1.  Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression.

Authors:  Yukihiko Shirayama; Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-08-01       Impact factor: 5.270

2.  Stereoselective and regiospecific hydroxylation of ketamine and norketamine.

Authors:  Zeruesenay Desta; Ruin Moaddel; Evan T Ogburn; Cong Xu; Anuradha Ramamoorthy; Swarajya Lakshmi Vattem Venkata; Mitesh Sanghvi; Michael E Goldberg; Marc C Torjman; Irving W Wainer
Journal:  Xenobiotica       Date:  2012-05-21       Impact factor: 1.908

3.  Ketamine's antidepressant action: beyond NMDA receptor inhibition.

Authors:  Kenji Hashimoto
Journal:  Expert Opin Ther Targets       Date:  2016-09-28       Impact factor: 6.902

4.  Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.

Authors:  M A Peltoniemi; T I Saari; N M Hagelberg; P Reponen; M Turpeinen; K Laine; P J Neuvonen; K T Olkkola
Journal:  Clin Pharmacol Ther       Date:  2011-06-29       Impact factor: 6.875

5.  Drug interaction study between bupropion and ticlopidine in male CF-1 mice.

Authors:  Jillissa Christine Molnari; Hazem EmadEldin Hassan; Bryant Michael Moeller; Alan Lewis Myers
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

6.  Pharmacological interaction with the sigma1 (σ1)-receptor in the acute behavioral effects of antidepressants.

Authors:  Vanessa Villard; Johann Meunier; Nathalie Chevallier; Tangui Maurice
Journal:  J Pharmacol Sci       Date:  2011       Impact factor: 3.337

7.  Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.

Authors:  Chun Yang; Qian Ren; Youge Qu; Ji-Chun Zhang; Min Ma; Chao Dong; Kenji Hashimoto
Journal:  Biol Psychiatry       Date:  2017-05-31       Impact factor: 13.382

8.  Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation.

Authors:  Ji-Chun Zhang; Wei Yao; Chao Dong; Chun Yang; Qian Ren; Min Ma; Mei Han; Jin Wu; Yusuke Ushida; Hiroyuki Suganuma; Kenji Hashimoto
Journal:  J Nutr Biochem       Date:  2016-10-11       Impact factor: 6.048

9.  Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations.

Authors:  J D Adams; T A Baillie; A J Trevor; N Castagnoli
Journal:  Biomed Mass Spectrom       Date:  1981-11

10.  Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling.

Authors:  Suresh K Balani; Ping Li; Joanne Nguyen; Kym Cardoza; Hang Zeng; Dun-Xue Mu; Jing-Tao Wu; Liang-Shang Gan; Frank W Lee
Journal:  Drug Metab Dispos       Date:  2004-06-24       Impact factor: 3.922

View more
  24 in total

1.  Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model.

Authors:  Kai Zhang; Hidetoh Toki; Yuko Fujita; Min Ma; Lijia Chang; Youge Qu; Shingo Harada; Tetsuhiro Nemoto; Akiko Mizuno-Yasuhira; Jun-Ichi Yamaguchi; Shigeyuki Chaki; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2018-09-13       Impact factor: 4.530

Review 2.  Ketamine: Leading us into the future for development of antidepressants.

Authors:  Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal:  Behav Brain Res       Date:  2020-02-02       Impact factor: 3.332

Review 3.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

4.  What role does the (2R,6R)-hydronorketamine metabolite play in the antidepressant-like and abuse-related effects of (R)-ketamine?

Authors:  Todd M Hillhouse; Remington Rice; Joseph H Porter
Journal:  Br J Pharmacol       Date:  2019-08-17       Impact factor: 8.739

Review 5.  Rodent ketamine depression-related research: Finding patterns in a literature of variability.

Authors:  Andrew J Polis; Paul J Fitzgerald; Pho J Hale; Brendon O Watson
Journal:  Behav Brain Res       Date:  2019-08-13       Impact factor: 3.332

6.  Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search.

Authors:  Jordi Bonaventura; Juan L Gomez; Meghan L Carlton; Sherry Lam; Marta Sanchez-Soto; Patrick J Morris; Ruin Moaddel; Hye Jin Kang; Panos Zanos; Todd D Gould; Craig J Thomas; David R Sibley; Carlos A Zarate; Michael Michaelides
Journal:  Mol Psychiatry       Date:  2022-06-29       Impact factor: 15.992

7.  Comments to behavioral tests for antidepressant-like actions of (2R,6R)-hydroxynorketamine by Bonaventura et al.

Authors:  Lijia Chang; Kenji Hashimoto
Journal:  Mol Psychiatry       Date:  2022-09-13       Impact factor: 13.437

8.  Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.

Authors:  Briana K Chen; Victor M Luna; Christina T LaGamma; Xiaoming Xu; Shi-Xian Deng; Raymond F Suckow; Thomas B Cooper; Abhishek Shah; Rebecca A Brachman; Indira Mendez-David; Denis J David; Alain M Gardier; Donald W Landry; Christine A Denny
Journal:  Neuropsychopharmacology       Date:  2020-05-17       Impact factor: 7.853

9.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.

Authors:  Dmitriy Matveychuk; Rejish K Thomas; Jennifer Swainson; Atul Khullar; Mary-Anne MacKay; Glen B Baker; Serdar M Dursun
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11

10.  Determination of Diffusion Kinetics of Ketamine in Brain Tissue: Implications for in vitro Mechanistic Studies of Drug Actions.

Authors:  Zachary Geiger; Brett VanVeller; Zarin Lopez; Abdel K Harrata; Kathryn Battani; Lauren Wegman-Points; Li-Lian Yuan
Journal:  Front Neurosci       Date:  2021-07-01       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.